Therapeutic thrombocytapheresis short-term efficacy and hematologic impact: comparing MNC procedure of COBE spectra and PLT-5d C5L procedure of COM.TEC.

Due to the disruption in the supply of consumables for platelet separation on the COBE Spectra blood component separator in China, we have performed therapeutic thrombocytapheresis using its mononuclear cell collection procedure (MNC procedure) and compared it with the therapy by COM.TEC platelet donation procedure to compare the influence on patient blood cell indicators. Therapeutic thrombocytapheresis was conducted 69 and 35 times on 38 and 15 clonal thrombocytosis patients using the MNC procedure with the COBE Spectra (MNC group) and the PLT-5d C5L procedure of the COM.TEC platelet donation package (PLT-5d C5L group), respectively. In the MNC and PLT-5d C5L groups, the therapy durations and the processed blood volumes were similar: platelet removal rates, 60.56% (53.59-75.81%) and (84.95 ± 39.46)% (z = 3.017, p < 0.01); white blood cell (WBC) loss values, 2.85 (2.02-3.83) × 10/L and 0.69 (0.23-1.47) × 10/L (z = 8.307, p < 0.001); and haemoglobin (Hb) loss values, 0.75 (0.50-1.09) g/L and 0.03 (0.02-0.20) g/L (z = 8.311, p < 0.001) in the MNC and PLT-5d C5L groups, respectively. However, the WBC count decreased by 1.28 (- 0.84 to 2.49) × 10/L and (2.97 ± 3.49) × 10/L (z = 2.825, p < 0.01), and the Hb level decreased by (3.38 ± 9.36) g/L and (9.06 ± 7.05) g/L (t = - 3.158, p < 0.01) in the MNC and PLT-5d C5L groups, respectively. The results show that, compared with the COBE Spectra MNC procedure, although the COM.TEC platelet donation package PLT-5d C5L procedure demonstrated higher therapeutic thrombocytapheresis efficiency, it also resulted in a greater decrease in WBCs and Hb.